B-Rag2 KO rats_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

United States

China

France

Germany

Netherlands

United Kingdom

Japan

South Korea

Israel

Australia

Hong Kong, China

New Zealand

Russia

Singapore

Taiwan, China

India

Aland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua & Barbuda

Argentina

Armenia

Aruba

Ascension Island

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

British Indian Ocean Territory

British Virgin Islands

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Canary Islands

Cape Verde

Caribbean Netherlands

Cayman Islands

Central African Republic

Ceuta & Melilla

Chad

Chile

Christmas Island

Cocos (Keeling) Islands

Colombia

Comoros

Congo - Brazzaville

Congo - Kinshasa

Cook Islands

Costa Rica

Côte d’Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czechia

Denmark

Diego Garcia

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

Indonesia

Iran

Iraq

Ireland

Isle of Man

Italy

Jamaica

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macau, China

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

New Caledonia

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

North Korea

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territories

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn Islands

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Rwanda

Samoa

San Marino

São Tomé & Príncipe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Sint Maarten

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia & South Sandwich Islands

South Sudan

Spain

Sri Lanka

St. Barthélemy

St. Helena

St. Kitts & Nevis

St. Lucia

St. Martin

St. Pierre & Miquelon

St. Vincent & Grenadines

Sudan

Suriname

Svalbard & Jan Mayen

Swaziland

Sweden

Switzerland

Syria

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad & Tobago

Tristan da Cunha

Tunisia

Turkey

Turkmenistan

Turks & Caicos Islands

Tuvalu

U.S. Outlying Islands

U.S. Virgin Islands

Uganda

Ukraine

United Arab Emirates

United Nations

Uruguay

Uzbekistan

Vanuatu

Vatican City

Venezuela

Vietnam

Wallis & Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

Home

Animal models

Animal / cell resources

Immunodeficient Mice/Rats

Other Immunodeficient Mice/Rats

Text

B-Rag2 KO rats

Strain Name	SD-Rag2^tm1/Bcgen	Common Name	B-Rag2 KO rats
Background	SD	Catalog number	210511
Aliases	RAG-2

B-Rag2 KO rats exhibit the smallest thymus size

from clipboard

The thymus sizes of B-Rag2 KO rats were reduced compared to that of wild-type SD rats. Gross anatomy of thymuses in male and female wild-type SD rats and B-Rag2 KO rats were showed (n=3, 7-week-old). Thymus sizes of B-Rag2 KO rats were significantly reduced compared to that of wild-type SD rats.

B-Rag2 KO rats exhibit the significantly reduced thymus and spleen weight

from clipboard

The size and weight of thymus and spleen of B-Rag2 KO rats were significantly reduced compared to that of wild-type SD rats. Thymus and spleen were isolated from male and female wild-type SD rats and B-Rag2 KO rats and weighed (n=3, 7-week-old). Thymus size and weight of B-Rag2 KO rats were significantly reduced compared to that of wild-type SD rats. Spleen size and weight of B-Rag2 KO rats were significantly reduced compared to that of wild-type SD rats.

Analysis of leukocyte subpopulation in thymus

from clipboard

Complete loss of T cells in thymus of homozygous B-Rag2 KO rats. Thymuses were collected from male and female wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. A. Representative FACS plots. B. Statistical analysis of FACS. Results showed that total T cells, CD4+ T cells and CD8+ T cells were only detectable in thymuses of wild-type SD rats. But none of the T cells were detectable in thymuses of B-Rag2 KO rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in spleen of male rats

from clipboard

Complete loss of T cells and B cells in spleen of homozygous male B-Rag2 KO rats. Spleens were collected from male wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in spleen of B-Rag2 KO rats. The percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in spleen of female rats

from clipboard

Complete loss of T cells and B cells in spleen of homozygous female B-Rag2 KO rats. Spleens were collected from female wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in spleen of B-Rag2 KO rats. The percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in spleen

from clipboard

Complete loss of T cells and B cells in spleen of homozygous male and female B-Rag2 KO rats. Spleens were collected from male and female wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in spleen of B-Rag2 KO rats. The percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in blood of male rats

from clipboard

Complete loss of T cells and B cells in blood of homozygous male B-Rag2 KO rats. Blood cells were collected from male wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in blood of B-Rag2 KO rats. The percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in blood of female rats

from clipboard

Complete loss of T cells and B cells in blood of homozygous female B-Rag2 KO rats. Blood cells were collected from female wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in blood of B-Rag2 KO rats. The percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in blood

from clipboard

Complete loss of T cells and B cells in blood of homozygous male and female B-Rag2 KO rats. Blood cells were collected from male and female wild-type SD rats and B-Rag2 KO rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in blood of B-Rag2 KO rats. The percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

THP-1 human leukemia xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of THP-1 cells in B-Rag2 KO rats. Human acute monocytic leukemia cell line THP-1 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, THP-1 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.

NCI-H2122 human lung cancer xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of NCI-H2122 cells in B-Rag2 KO rats. Human non-small cell lung cancer cell line NCI-H2122 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, NCI-H2122 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.

H460 human lung cancer xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of H460 cells in B-Rag2 KO rats. Human lung cancer cell line H460 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, H460 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.

NCI-H1373 human lung cancer xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of NCI-H1373 cells in B-Rag2 KO rats. Human lung cancer cell line NCI-H1373 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, NCI-H1373 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.

A549 human lung cancer xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of A549 cells in B-Rag2 KO rats. Human lung cancer cell line A549 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, A549 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.

RT-112 human bladder cancer xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of RT-112 cells in B-Rag2 KO rats. Human bladder cancer cell line RT-112 (1x10⁷) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, RT-112 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.

HCC1954 human breast cancer xenograft model in B-Rag2 KO rats

from clipboard

Subcutaneous homograft tumor growth of HCC1954 cells in B-Rag2 KO rats. Human breast cancer cell line HCC1954 (25x10⁶) were mixed with Matrigel and inoculated subcutaneously into B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, HCC1954 cells were able to establish tumors in B-Rag2 KO rats, indicating that B-Rag2 KO rats can be used for efficacy studies.